- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05908682
Sikkerhed for gravide personer, der er udsat for Ibrexafungerp, inklusive spædbørnsudfald
En enkeltarms sikkerhedsundersøgelse af forsøgspersoner, der er udsat for Ibrexafungerp, mens de er gravide, inklusive spædbørnsresultater op til et år
This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
This is a single-arm safety study which comprises an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age who were exposed to ibrexafungerp during pregnancy, or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, and are volunteering to take part in this study. Subjects will be monitored starting from exposure during pregnancy until one year after live delivery.
Information on pregnancy outcomes and complications as well as fetal/neonatal/infant outcomes will be collected during the timeframe described in the protocol.
Subjects can enroll in the study by calling the telephone number directly (1-888-982-7299) or through SCYNEXIS BREXAFEMME Pregnancy Study Webpage, OR her healthcare provider (HCP) can, with her consent, enroll her on her behalf.
Data will be collected both retrospectively and prospectively using a variety of questionnaire that will be completed by the representative based on interview with the subject and/or HCP
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Sanjeev Miglani, MD
- Telefonnummer: +91-9910533655
- E-mail: sanjeev.miglani@awinsals.com
Studiesteder
-
-
Vasant Vihar
-
New Delhi, Vasant Vihar, Indien, 110057
- Rekruttering
- AWINSA
-
Kontakt:
- Sanjeev Miglani, MD
- Telefonnummer: +91-9910533655
- E-mail: sanjeev.miglani@awinsals.com
-
Ledende efterforsker:
- Sanjeev Miglani, MD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
The study population will include women who were exposed to ibrexafungerp at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving last dose of ibrexafungerp, volunteering to take part in this study.
Beskrivelse
Inclusion Criteria:
-
Exposure to ibrexafungerp during pregnancy or if conception is estimated to have occurred within 4 days of the last dose of ibrexafungerp
-
Subject and/or parent/legal representative consents to participate and agrees to the conditions and requirements of the study including the interview schedule/completion of questionnaire and release of medical records
- Subject can be identified by the sponsor or HCP, in terms of confirmed pregnancy.
A self-reported pregnancy will be considered as confirmed pregnancy if the Urine Pregnancy Test (UPT) result is positive.
- A woman can self-enroll in the study or her healthcare provider (HCP), with her consent, can enroll her on her behalf.
Exclusion Criteria:
- Females who were not exposed to safety study medications during pregnancy
- Refusal to participate in the study
- An inability to provide an accurate medical history or give informed consent
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: CASE_ONLY
- Tidsperspektiver: OTHER
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
Study Cohort
Subjects who have been treated with Brexafemme (Ibrexafungerp) at any time during pregnancy or whose conception is estimated to have occurred within four days after receiving the last dose of Brexafemme. |
This is not an interventional study |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Major Structural Defects
Tidsramme: From Brexafemme exposure up to one year after birth
|
To collect and describe selected fetal/neonatal/infant outcomes (i.e., major and minor congenital malformations, small for gestational age, and postnatal growth and development) at birth and through up to the first year of life of infants born to women exposed to ibrexafungerp during the defined pregnancy exposure window |
From Brexafemme exposure up to one year after birth
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
To collect and describe pregnancy outcomes
Tidsramme: From Brexafemme exposure up to one year post birth
|
Live birth, spontaneous abortions, stillbirths, elective abortions, and preterm births |
From Brexafemme exposure up to one year post birth
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Urogenitale sygdomme
- Genitale sygdomme
- Mundsygdomme
- Stomatognatiske sygdomme
- Urogenitale sygdomme hos kvinder
- Kvinders urogenitale sygdomme og graviditetskomplikationer
- Infektioner
- Kønssygdomme, kvindelige
- Bakterielle infektioner og mykoser
- Vulva sygdomme
- Vulvitis
- Vaginitis
- Mykoser
- Vaginale sygdomme
- Candidiasis
- Candidiasis, Vulvovaginal
- Vulvovaginitis
- Candidiasis, oral
Andre undersøgelses-id-numre
- 222030
- SCY-078-401 (Anden identifikator: Scynexis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .